|Aldeyra Therapeutics Inc., of Lexington, Mass.||Reproxalap||Reactive aldehyde species inhibitor||Dry eye disease||FDA agreed to the use of reactive aldehyde species as an objective sign in clinical trials|
|Algernon Pharmaceuticals Inc., of Vancouver, British Columbia||NP-120 (ifenprodil)||NMDA receptor antagonist||COVID-19||FDA cleared IND for phase IIb/III study|
|Anavex Life Sciences Corp., of New York||Anavex 2-73 (blarcamesine)||Activates sigma-1 receptor||Early Alzheimer’s disease||Health Canada issued a no objection letter for the phase IIb/III ANAVEX2-73-AD-004 study; Medicines and Healthcare products Regulatory Agency in the U.K. approved the CTA for the study|
|Can-Fite Biopharma Ltd., of Petach Tikva, Israel||Namodenoson||A3 adenosine receptor agonist||Hepatocellular carcinoma||Concluded a meeting with the EMA's Scientific Advice Working Party; plans to run 1 pivotal trial for registration in the U.S. and EU|
|Elixirgen Therapeutics Inc., of Baltimore||EXG-5003||Self-replicating RNA vaccine expressing the receptor binding domain of the SARS-CoV-2 spike protein||COVID-19 prophylaxis||Completed pre-IND meeting with the FDA|
|Elixirgen Therapeutics Inc., of Baltimore||EXG-34217||Autologous cell therapy||Telomere biology disorders with bone marrow failure||FDA approved the IND for the phase I/II study|
For more information about individual companies and/or products, see Cortellis.